Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2020 Sep 4

PMID 32882243

Citations 102

Authors

Raymond L Benza

Manreet K Kanwar

Amresh Raina

Jacqueline V Scott

Carol L Zhao

Mona Selej

C Greg Elliott

Harrison W Farber

Affiliations

Soon will be listed here.

Abstract

Background: Achievement of low-risk status is a treatment goal in pulmonary arterial hypertension (PAH). Risk assessment often is performed using multiparameter tools, such as the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator. Risk calculators that assess fewer variables without compromising validity may expedite risk assessment in the routine clinic setting. We describe the development and validation of REVEAL Lite 2, an abridged version of REVEAL 2.0.

Research Question: Can a simplified version of the REVEAL 2.0 risk assessment calculator for patients with PAH be developed and validated?

Study Design And Methods: REVEAL Lite 2 includes six noninvasive variables-functional class (FC), vital signs (systolic BP [SBP] and heart rate), 6-min walk distance (6MWD), brain natriuretic peptide (BNP)/N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and renal insufficiency (by estimated glomerular filtration rate [eGFR])-and was validated in a series of analyses (Kaplan-Meier, concordance index, Cox proportional hazard model, and multivariate analysis).

Results: REVEAL Lite 2 approximates REVEAL 2.0 at discriminating low, intermediate, and high risk for 1-year mortality in patients in the REVEAL registry. The model indicated that the most highly predictive REVEAL Lite 2 parameter was BNP/NT-proBNP, followed by 6MWD and FC. Even if multiple, less predictive variables (heart rate, SBP, eGFR) were missing, REVEAL Lite 2 still discriminated among risk groups.

Interpretation: REVEAL Lite 2, an abridged version of REVEAL 2.0, provides a simplified method of risk assessment that can be implemented routinely in daily clinical practice. REVEAL Lite 2 is a robust tool that provides discrimination among patients at low, intermediate, and high risk of 1-year mortality.

Trial Registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

Citing Articles

Contribution of QRS Prolongation to Transplant-Free Survival in Sarcoidosis-Related Pulmonary Hypertension.

Rodriguez J, Zhang H, Mesfin N, Klings E, Lui J Pulm Circ. 2025; 15(1):e70021.

PMID: 40071062 PMC: 11894461. DOI: 10.1002/pul2.70021.

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.

Pulido T, de la Cruz-Perez S, Valencia D, Conde R, Lescano A, Zayas N Int J Cardiol Congenit Heart Dis. 2025; 19:100573.

PMID: 40066342 PMC: 11891735. DOI: 10.1016/j.ijcchd.2025.100573.

Association of pulmonary hypertension-targeted therapy and survival in precapillary pulmonary hypertension with mean pulmonary arterial pressure between 21 and 24 mmHg.

Yogeswaran A, Funderich M, Olschewski H, Kovacs G, Kiely D, Lawrie A ERJ Open Res. 2025; 11(1).

PMID: 40008170 PMC: 11849103. DOI: 10.1183/23120541.00466-2024.

An Unsupervised Approach to Derive Right Ventricular Pressure-Volume Loop Phenotypes in Pulmonary Hypertension.

Sivakumar N, Zhang C, Chang-Chien C, Gu P, Li Y, Yang Y Pulm Circ. 2025; 15(1):e70057.

PMID: 39990646 PMC: 11842459. DOI: 10.1002/pul2.70057.

Heart Rate Variability in Pulmonary Arterial Hypertension.

Gyawali B, Roto D, Lachant M, White R, Lachant D Pulm Circ. 2025; 15(1):e70048.

PMID: 39925946 PMC: 11806521. DOI: 10.1002/pul2.70048.

References

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

Raina A, Humbert M . Risk assessment in pulmonary arterial hypertension. Eur Respir Rev. 2016; 25(142):390-398. PMC: 9487550. DOI: 10.1183/16000617.0077-2016. View

White R, Jerjes-Sanchez C, Meyer G, Pulido T, Sepulveda P, Wang K . Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2019; 201(6):707-717. PMC: 7068822. DOI: 10.1164/rccm.201908-1640OC. View

Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O . The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. Am J Respir Crit Care Med. 2017; 197(7):860-868. DOI: 10.1164/rccm.201709-1840PP. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S . A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017; 39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257. View

Benza R, Farber H, Selej M, Gomberg-Maitland M . Assessing risk in pulmonary arterial hypertension: what we know, what we don't. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.01353-2017. View

Hoeper M, Kramer T, Pan Z, Eichstaedt C, Spiesshoefer J, Benjamin N . Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00740-2017. View

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

10.

Benza R, Gomberg-Maitland M, Miller D, Frost A, Frantz R, Foreman A . The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2011; 141(2):354-362. DOI: 10.1378/chest.11-0676. View

11.

Galie N, Channick R, Frantz R, Grunig E, Jing Z, Moiseeva O . Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2018; 53(1). PMC: 6351343. DOI: 10.1183/13993003.01889-2018. View

12.

Simons J, Mann E, Pierozynski A . Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. Adv Ther. 2019; 36(9):2351-2363. PMC: 6822842. DOI: 10.1007/s12325-019-01030-4. View

13.

Benza R, Gomberg-Maitland M, Elliott C, Farber H, Foreman A, Frost A . Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019; 156(2):323-337. DOI: 10.1016/j.chest.2019.02.004. View

14.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

15.

Sitbon O, Nikkho S, Benza R, Cq Deng C, Farber H, Gomberg-Maitland M . Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulm Circ. 2020; 10(4):2045894020962960. PMC: 7682238. DOI: 10.1177/2045894020962960. View

16.

Farber H, Benza R . Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?. Am J Respir Crit Care Med. 2018; 197(7):843-845. DOI: 10.1164/rccm.201801-0042ED. View

17.

Anderson J, Lau E, Lavender M, Benza R, Celermajer D, Collins N . Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. Chest. 2019; 157(1):162-172. DOI: 10.1016/j.chest.2019.08.2203. View

18.

Kanwar M, Gomberg-Maitland M, Hoeper M, Pausch C, Pittrow D, Strange G . Risk stratification in pulmonary arterial hypertension using Bayesian analysis. Eur Respir J. 2020; 56(2). PMC: 7495922. DOI: 10.1183/13993003.00008-2020. View

19.

Pulido T, Adzerikho I, Channick R, Delcroix M, Galie N, Ghofrani H . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9):809-18. DOI: 10.1056/NEJMoa1213917. View